@article{Leroy2025,
abstract = {BACKGROUND: The cerebrospinal fluid (CSF) A$\beta$(42/40) ratio has proven to be a more  reliable biomarker for amyloid pathology than CSF A$\beta$(42) in Alzheimer's disease (AD), helping to correctly classify patients with positive tau biomarkers (T+) that would otherwise have remained outside of the AD continuum. It was shown that the A$\beta$(42/40) ratio better captures a relative decrease of A$\beta$(42) in patients with high CSF A$\beta$. However, whether patients with high-amyloid (HiA) AD, in whom A+ is defined by the A$\beta$(42/40) ratio, exactly compare with their low-amyloid (LoA) counterparts, in whom A+ is defined by A$\beta$(42) solely, deserves further analysis. METHODS: We retrospectively included patients with A+T+ AD and evidence of cognitive and neurodegenerative changes (N+). LoA patients were operationally defined as patients with T+N+ and low CSF A$\beta$(42), while HiA patients were defined as patients with T+N+ and normal CSF A$\beta$(42) but abnormal A$\beta$(42/40) ratio. Tau CSF biomarkers, neuropsychological profile, rates of cognitive decline, structural and metabolic imaging, ApoE genotype and brain neuropathology were compared between the HiA and LoA groups. RESULTS: At the time of the lumbar puncture, LoA patients were significantly younger than the HiA patients (68.9±8.7years vs. 71.8±9.4; P=0.0015) and had a lower Mini-Mental Status Examination (MMSE) (18.7±6.4 vs. 20.7±6.2; P=0.0005). There was no difference in the neuropsychological profile nor in the annual rates of cognitive decline between the two groups with early AD. No differences were retrieved between groups on CSF Tau and P-Tau biomarkers, atrophy and brain metabolism, distribution of the APOE4 allele and APOE4/E4 genotype, and neuropathology. CONCLUSIONS: Overall, our study supports the surrogate use of the A$\beta$(42/40) ratio as an equivalent to A$\beta$(42) to define AD. We showed that HiA CSF profiles were not associated with differences in cognition, brain structures and metabolism, APOE genotype tau CSF biomarkers or the rates of cognitive decline, but may be the associated with later-onset and early-stage AD.},
author = {Leroy, M{\'{e}}lanie and Aziz, Anne Laure and Schraen, Susanna and Deramecourt, Vincent and Skrobala, Emilie and Lecerf, Simon and Pasquier, Florence and Huin, Vincent and Bertoux, Maxime and Lebouvier, Thibaud},
doi = {10.1016/j.neurol.2025.02.004},
issn = {0035-3787 (Print)},
journal = {Revue neurologique},
language = {eng},
month = {mar},
pmid = {40057456},
title = {{Comparing high and low amyloid producers in Alzheimer's disease: An in-depth  analysis.}},
year = {2025}
}

{"_id":"PKkSEAYxn83sFwKbd","bibbaseid":"leroy-aziz-schraen-deramecourt-skrobala-lecerf-pasquier-huin-etal-comparinghighandlowamyloidproducersinalzheimersdiseaseanindepthanalysis-2025","author_short":["Leroy, M.","Aziz, A. L.","Schraen, S.","Deramecourt, V.","Skrobala, E.","Lecerf, S.","Pasquier, F.","Huin, V.","Bertoux, M.","Lebouvier, T."],"bibdata":{"bibtype":"article","type":"article","abstract":"BACKGROUND: The cerebrospinal fluid (CSF) A$β$(42/40) ratio has proven to be a more reliable biomarker for amyloid pathology than CSF A$β$(42) in Alzheimer's disease (AD), helping to correctly classify patients with positive tau biomarkers (T+) that would otherwise have remained outside of the AD continuum. It was shown that the A$β$(42/40) ratio better captures a relative decrease of A$β$(42) in patients with high CSF A$β$. However, whether patients with high-amyloid (HiA) AD, in whom A+ is defined by the A$β$(42/40) ratio, exactly compare with their low-amyloid (LoA) counterparts, in whom A+ is defined by A$β$(42) solely, deserves further analysis. METHODS: We retrospectively included patients with A+T+ AD and evidence of cognitive and neurodegenerative changes (N+). LoA patients were operationally defined as patients with T+N+ and low CSF A$β$(42), while HiA patients were defined as patients with T+N+ and normal CSF A$β$(42) but abnormal A$β$(42/40) ratio. Tau CSF biomarkers, neuropsychological profile, rates of cognitive decline, structural and metabolic imaging, ApoE genotype and brain neuropathology were compared between the HiA and LoA groups. RESULTS: At the time of the lumbar puncture, LoA patients were significantly younger than the HiA patients (68.9±8.7years vs. 71.8±9.4; P=0.0015) and had a lower Mini-Mental Status Examination (MMSE) (18.7±6.4 vs. 20.7±6.2; P=0.0005). There was no difference in the neuropsychological profile nor in the annual rates of cognitive decline between the two groups with early AD. No differences were retrieved between groups on CSF Tau and P-Tau biomarkers, atrophy and brain metabolism, distribution of the APOE4 allele and APOE4/E4 genotype, and neuropathology. CONCLUSIONS: Overall, our study supports the surrogate use of the A$β$(42/40) ratio as an equivalent to A$β$(42) to define AD. We showed that HiA CSF profiles were not associated with differences in cognition, brain structures and metabolism, APOE genotype tau CSF biomarkers or the rates of cognitive decline, but may be the associated with later-onset and early-stage AD.","author":[{"propositions":[],"lastnames":["Leroy"],"firstnames":["Mélanie"],"suffixes":[]},{"propositions":[],"lastnames":["Aziz"],"firstnames":["Anne","Laure"],"suffixes":[]},{"propositions":[],"lastnames":["Schraen"],"firstnames":["Susanna"],"suffixes":[]},{"propositions":[],"lastnames":["Deramecourt"],"firstnames":["Vincent"],"suffixes":[]},{"propositions":[],"lastnames":["Skrobala"],"firstnames":["Emilie"],"suffixes":[]},{"propositions":[],"lastnames":["Lecerf"],"firstnames":["Simon"],"suffixes":[]},{"propositions":[],"lastnames":["Pasquier"],"firstnames":["Florence"],"suffixes":[]},{"propositions":[],"lastnames":["Huin"],"firstnames":["Vincent"],"suffixes":[]},{"propositions":[],"lastnames":["Bertoux"],"firstnames":["Maxime"],"suffixes":[]},{"propositions":[],"lastnames":["Lebouvier"],"firstnames":["Thibaud"],"suffixes":[]}],"doi":"10.1016/j.neurol.2025.02.004","issn":"0035-3787 (Print)","journal":"Revue neurologique","language":"eng","month":"mar","pmid":"40057456","title":"Comparing high and low amyloid producers in Alzheimer's disease: An in-depth analysis.","year":"2025","bibtex":"@article{Leroy2025,\nabstract = {BACKGROUND: The cerebrospinal fluid (CSF) A$\\beta$(42/40) ratio has proven to be a more reliable biomarker for amyloid pathology than CSF A$\\beta$(42) in Alzheimer's disease (AD), helping to correctly classify patients with positive tau biomarkers (T+) that would otherwise have remained outside of the AD continuum. It was shown that the A$\\beta$(42/40) ratio better captures a relative decrease of A$\\beta$(42) in patients with high CSF A$\\beta$. However, whether patients with high-amyloid (HiA) AD, in whom A+ is defined by the A$\\beta$(42/40) ratio, exactly compare with their low-amyloid (LoA) counterparts, in whom A+ is defined by A$\\beta$(42) solely, deserves further analysis. METHODS: We retrospectively included patients with A+T+ AD and evidence of cognitive and neurodegenerative changes (N+). LoA patients were operationally defined as patients with T+N+ and low CSF A$\\beta$(42), while HiA patients were defined as patients with T+N+ and normal CSF A$\\beta$(42) but abnormal A$\\beta$(42/40) ratio. Tau CSF biomarkers, neuropsychological profile, rates of cognitive decline, structural and metabolic imaging, ApoE genotype and brain neuropathology were compared between the HiA and LoA groups. RESULTS: At the time of the lumbar puncture, LoA patients were significantly younger than the HiA patients (68.9±8.7years vs. 71.8±9.4; P=0.0015) and had a lower Mini-Mental Status Examination (MMSE) (18.7±6.4 vs. 20.7±6.2; P=0.0005). There was no difference in the neuropsychological profile nor in the annual rates of cognitive decline between the two groups with early AD. No differences were retrieved between groups on CSF Tau and P-Tau biomarkers, atrophy and brain metabolism, distribution of the APOE4 allele and APOE4/E4 genotype, and neuropathology. CONCLUSIONS: Overall, our study supports the surrogate use of the A$\\beta$(42/40) ratio as an equivalent to A$\\beta$(42) to define AD. We showed that HiA CSF profiles were not associated with differences in cognition, brain structures and metabolism, APOE genotype tau CSF biomarkers or the rates of cognitive decline, but may be the associated with later-onset and early-stage AD.},\nauthor = {Leroy, M{\\'{e}}lanie and Aziz, Anne Laure and Schraen, Susanna and Deramecourt, Vincent and Skrobala, Emilie and Lecerf, Simon and Pasquier, Florence and Huin, Vincent and Bertoux, Maxime and Lebouvier, Thibaud},\ndoi = {10.1016/j.neurol.2025.02.004},\nissn = {0035-3787 (Print)},\njournal = {Revue neurologique},\nlanguage = {eng},\nmonth = {mar},\npmid = {40057456},\ntitle = {{Comparing high and low amyloid producers in Alzheimer's disease: An in-depth analysis.}},\nyear = {2025}\n}\n","author_short":["Leroy, M.","Aziz, A. L.","Schraen, S.","Deramecourt, V.","Skrobala, E.","Lecerf, S.","Pasquier, F.","Huin, V.","Bertoux, M.","Lebouvier, T."],"key":"Leroy2025","id":"Leroy2025","bibbaseid":"leroy-aziz-schraen-deramecourt-skrobala-lecerf-pasquier-huin-etal-comparinghighandlowamyloidproducersinalzheimersdiseaseanindepthanalysis-2025","role":"author","urls":{},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://nextcloud.univ-lille.fr/index.php/s/ZN4QZ7dH9iNaNWE/download/Interactions.bib","dataSources":["ECsXQHgbAjNJDKiJ7"],"keywords":[],"search_terms":["comparing","high","low","amyloid","producers","alzheimer","disease","depth","analysis","leroy","aziz","schraen","deramecourt","skrobala","lecerf","pasquier","huin","bertoux","lebouvier"],"title":"Comparing high and low amyloid producers in Alzheimer's disease: An in-depth analysis.","year":2025}